The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas
Cancer Chemotherapy and Pharmacology, 06/08/2012
Clinical Article
Grossman R et al. – The findings suggest that there were no statistically significant changes in temozolomide (TMZ) pharmacokinetics before or after BEV in the athymic rat U87 intracranial glioma model. BEV and TMZ are being investigated as a combination therapy in several ongoing studies for patients with glioma. These data reassuringly suggest that BEV does not significantly change the ECF tumor concentrations of TMZ in either tumor–bearing or normal brain when dosed 36 h prior to TMZ.
